All In Biotech

Drug Trial Radar · NCT05432544

Safety and Tolerability of SHR-1918 in Healthy Subjects

A Phase 1, Randomized, Double Blind, Dose-escalation, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Injection of SHR-1918 Injection in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jul 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

72

Actual

Start

Jun 27, 2022

Primary completion

Dec 11, 2023

Study completion Dec 12, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the safety and tolerability of SHR-1918 injection in healthy subjects. In addition, this study will provide information on pharmacokinetics and pharmacodynamics of SHR-1918 injection in healthy subjects.

Conditions

  • Hyperlipemia

Interventions

  • SHR-1918Drug

    Ascending dose

  • SHR-1918 placeboDrug

    Ascending dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the number of subjects with adverse events (AEs)Time frame: up to day 190
  2. To assess the number of subjects with serious adverse events (SAEs)Time frame: up to day 190

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.